Company profile: Heidelberg Pharma
1.1 - Company Overview
Company description
- Provider of pre-clinical drug discovery and development services for anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries, including explorative pharmacology, drug metabolism and pharmacokinetics analysis, and molecular biology. Also researches, produces, and clinically develops Antibody Amanitin Conjugates (ATACs) using amanitin for cancer therapies.
Products and services
- ATACs: Custom-engineered Antibody Amanitin Conjugates that merge antibodies’ affinity and specificity with potent small-molecule toxicity using Amanitin payloads to selectively target cancer cells
- ADC Drug Development: Clinically-focused program that architects, researches, and produces Antibody Amanitin Conjugates using Amanitin from the death cap mushroom to clinically develop targeted cancer therapies
- Pre-clinical Drug Discovery and Development Services: Preclinical offering that delivers explorative pharmacology, drug metabolism and pharmacokinetics analysis, and molecular biology for anti-cancer and anti-inflammatory therapeutics to pharma and biotech
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Heidelberg Pharma
AdnaGen
HQ: Germany
Website
- Description: Provider of molecular genetic diagnostic testing systems for medical and clinical research laboratories, offering AdnaTest kits with reagents for immunomagnetic selection, mRNA isolation, and multiplex RT-PCR for tumor diagnostics, and focusing on genetic pre-disposition.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AdnaGen company profile →
Acrivon Therapeutics
HQ: United States
Website
- Description: Provider of precision oncology therapeutics and companion diagnostics, leveraging the AP3 platform to develop drugs and OncoSignature tests that match therapies to tumor-driving mechanisms. Pipeline includes ACR-368, a phase 2 DNA damage response kinase inhibitor for solid cancers, and ACR-2316, a preclinical selective dual WEE1/PKMYT1 inhibitor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acrivon Therapeutics company profile →
BioNovion
HQ: United States
Website
- Description: Provider of immune oncology antibody discovery and development focused on antibodies for the immune therapy of cancer; U.S.-based, founded in 2011 and acquired by Aduro BioTech in 2015.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioNovion company profile →
Arius Research
HQ: Canada
Website
- Description: Provider of biotechnology solutions centered on the discovery and development of antibody therapeutics, primarily targeting breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma, leveraging its FunctionFIRST platform to identify monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arius Research company profile →
hC Bioscience
HQ: United States
Website
- Description: Provider of engineered tRNA-based protein editing platforms and therapeutics, including PTCX (Patch) to suppress nonsense mutations in mRNA and restore full-length protein, SWTX (Switch) to mark disease-causing proteins for destruction, and engineered tRNA therapies to correct multiple mutant proteins across various disease indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full hC Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Heidelberg Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Heidelberg Pharma
2.2 - Growth funds investing in similar companies to Heidelberg Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Heidelberg Pharma
4.2 - Public trading comparable groups for Heidelberg Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →